Lv2
150 积分 2022-10-14 加入
Current knowledge and management of atrial fibrillation: consensus of Chinese experts 2021
3天前
已完结
The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
1年前
已完结
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
1年前
已完结
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
1年前
已完结
Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies
1年前
已关闭
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
1年前
已完结
Protein degraders enter the clinic — a new approach to cancer therapy
1年前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
1年前
已完结
LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
1年前
已完结
Development of a highly potent and selective degrader of LRRK2
1年前
已完结
皖公网安备34019202002308
